These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 18390833)

  • 1. Pyrrolidine dithiocarbamate restores endothelial cell membrane integrity and attenuates monocrotaline-induced pulmonary artery hypertension.
    Huang J; Kaminski PM; Edwards JG; Yeh A; Wolin MS; Frishman WH; Gewitz MH; Mathew R
    Am J Physiol Lung Cell Mol Physiol; 2008 Jun; 294(6):L1250-9. PubMed ID: 18390833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A nuclear factor-kappaB inhibitor pyrrolidine dithiocarbamate ameliorates pulmonary hypertension in rats.
    Sawada H; Mitani Y; Maruyama J; Jiang BH; Ikeyama Y; Dida FA; Yamamoto H; Imanaka-Yoshida K; Shimpo H; Mizoguchi A; Maruyama K; Komada Y
    Chest; 2007 Oct; 132(4):1265-74. PubMed ID: 17934115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of nuclear factor-κB in the lungs prevents monocrotaline-induced pulmonary hypertension in mice.
    Li L; Wei C; Kim IK; Janssen-Heininger Y; Gupta S
    Hypertension; 2014 Jun; 63(6):1260-9. PubMed ID: 24614212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disruption of endothelial-cell caveolin-1alpha/raft scaffolding during development of monocrotaline-induced pulmonary hypertension.
    Mathew R; Huang J; Shah M; Patel K; Gewitz M; Sehgal PB
    Circulation; 2004 Sep; 110(11):1499-506. PubMed ID: 15353500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pyrrolidine dithiocarbamate attenuates the development of monocrotaline-induced pulmonary arterial hypertension.
    Yavuz T; Uzun O; Macit A; Comunoglu C; Yavuz O; Silan C; Yuksel H; Yildirim HA
    Pathol Res Pract; 2013 May; 209(5):302-8. PubMed ID: 23582365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of AMPK prevents monocrotaline-induced pulmonary arterial hypertension by suppression of NF-κB-mediated autophagy activation.
    Zhai C; Shi W; Feng W; Zhu Y; Wang J; Li S; Yan X; Wang Q; Zhang Q; Chai L; Li C; Liu P; Li M
    Life Sci; 2018 Sep; 208():87-95. PubMed ID: 30009823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resveratrol inhibits monocrotaline-induced pulmonary arterial remodeling by suppression of SphK1-mediated NF-κB activation.
    Shi W; Zhai C; Feng W; Wang J; Zhu Y; Li S; Wang Q; Zhang Q; Yan X; Chai L; Liu P; Chen Y; Li M
    Life Sci; 2018 Oct; 210():140-149. PubMed ID: 30179628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Caveolin-1 expression during the progression of pulmonary hypertension.
    Huang J; Wolk JH; Gewitz MH; Mathew R
    Exp Biol Med (Maywood); 2012 Aug; 237(8):956-65. PubMed ID: 22890027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Forsythoside B Mitigates Monocrotaline-Induced Pulmonary Arterial Hypertension via Blocking the NF-κB Signaling Pathway to Attenuate Vascular Remodeling.
    Liu J; Fang G; Lan C; Qiu C; Yao L; Zhang Q; Hu J; Zhang Y; Yang Y; Zhang Y
    Drug Des Devel Ther; 2024; 18():767-780. PubMed ID: 38495631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progressive endothelial cell damage in an inflammatory model of pulmonary hypertension.
    Huang J; Wolk JH; Gewitz MH; Mathew R
    Exp Lung Res; 2010 Feb; 36(1):57-66. PubMed ID: 20128682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Baicalein attenuates monocrotaline-induced pulmonary arterial hypertension by inhibiting endothelial-to-mesenchymal transition.
    Shi R; Zhu D; Wei Z; Fu N; Wang C; Liu L; Zhang H; Liang Y; Xing J; Wang X; Wang Y
    Life Sci; 2018 Aug; 207():442-450. PubMed ID: 29969608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Baicalein attenuates monocrotaline-induced pulmonary arterial hypertension by inhibiting vascular remodeling in rats.
    Shi R; Wei Z; Zhu D; Fu N; Wang C; Yin S; Liang Y; Xing J; Wang X; Wang Y
    Pulm Pharmacol Ther; 2018 Feb; 48():124-135. PubMed ID: 29133079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A urotensin II receptor antagonist, KR36676, decreases vascular remodeling and inflammation in experimental pulmonary hypertension.
    Lee JH; Park BK; Oh KS; Yi KY; Lim CJ; Seo HW; Lee BH
    Int Immunopharmacol; 2016 Nov; 40():196-202. PubMed ID: 27611861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dihydromyricetin prevents monocrotaline-induced pulmonary arterial hypertension in rats.
    Li Q; Wang J; Zhu X; Zeng Z; Wu X; Xu Y; Xie J; Yu J
    Biomed Pharmacother; 2017 Dec; 96():825-833. PubMed ID: 29078260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ruscogenin attenuates monocrotaline-induced pulmonary hypertension in rats.
    Bi LQ; Zhu R; Kong H; Wu SL; Li N; Zuo XR; Zhou SM; Kou JP; Yu BY; Wang H; Xie WP
    Int Immunopharmacol; 2013 May; 16(1):7-16. PubMed ID: 23538027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic Normobaric Hypoxia Induces Pulmonary Hypertension in Rats: Role of NF-κB.
    Fan J; Fan X; Li Y; Ding L; Zheng Q; Guo J; Xia D; Xue F; Wang Y; Liu S; Gong Y
    High Alt Med Biol; 2016 Mar; 17(1):43-9. PubMed ID: 26788753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathophysiological roles of nuclear factor kappaB (NF-kB) in pulmonary arterial hypertension: effects of synthetic selective NF-kB inhibitor IMD-0354.
    Hosokawa S; Haraguchi G; Sasaki A; Arai H; Muto S; Itai A; Doi S; Mizutani S; Isobe M
    Cardiovasc Res; 2013 Jul; 99(1):35-43. PubMed ID: 23631839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [NF-κB inhibitor improves pulmonary vascular remodeling by reversing LPS-induced down-regulation of BMPRII].
    Zhou MJ; Xing YJ; Yang J
    Sheng Li Xue Bao; 2020 Oct; 72(5):541-550. PubMed ID: 33106824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 5-Aminosalicylic Acid Attenuates Monocrotaline-Induced Pulmonary Arterial Hypertension in Rats by Increasing the Expression of Nur77.
    Sun LY; Cai ZY; Pu J; Li J; Shen JY; Yang CD; He B
    Inflammation; 2017 Jun; 40(3):806-817. PubMed ID: 28213866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The protective effects of PCPA against monocrotaline-induced pulmonary arterial hypertension are mediated through the downregulation of NFAT-1 and NF-κB.
    Bai Y; Li ZX; Wang HL; Lian GC; Wang Y
    Int J Mol Med; 2017 Jul; 40(1):155-163. PubMed ID: 28560440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.